MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Pulse Biosciences Operating Income 2011-2026 | PLSE
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Pulse Biosciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -43.6 M | -58.1 M | -63 M | -50 M | -48 M | -37.5 M | -25.6 M | -9.52 M | -4.47 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.47 M | -63 M | -37.7 M |
Quarterly Operating Income Pulse Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -20.4 M | -20.3 M | -18 M | - | -13.7 M | -11.7 M | -10.6 M | - | -11.3 M | -10.2 M | -9.56 M | - | -18 M | -14 M | -17.3 M | - | -14.3 M | -14.8 M | -18.5 M | - | -12.9 M | - | - | -13.8 M | -11.7 M | -11.4 M | -10.1 M | -8.95 M | -10.8 M | -9.16 M | -8.67 M | -8.7 M | -7.49 M | -6.18 M | -3.2 M | -2.81 M | -2.77 M | -2.26 M | -1.68 M | -1.54 M | -1.23 M | -956 K | -743 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -743 K | -20.4 M | -9.99 M |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
14 M | $ 21.07 | 1.81 % | $ 10.7 B | USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 202.8 | -1.16 % | $ 58.3 B | USA |
 |
ICU Medical
ICUI
|
43 M | $ 151.86 | 0.14 % | $ 3.7 B | USA |
 |
iRhythm Technologies
IRTC
|
-116 M | $ 180.4 | -4.68 % | $ 5.63 B | USA |
 |
Repro Med Systems
KRMD
|
-10.3 M | $ 5.67 | -2.41 % | $ 259 M | USA |
 |
Masimo Corporation
MASI
|
-267 M | $ 140.04 | 1.54 % | $ 7.46 B | USA |
 |
Merit Medical Systems
MMSI
|
156 M | $ 86.37 | -7.31 % | $ 5.03 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-10.5 M | $ 8.03 | -1.95 % | $ 162 M | USA |
 |
Alcon
ALC
|
580 M | $ 80.27 | -0.43 % | $ 40.4 B |  Schweiz |
 |
Predictive Oncology
POAI
|
-10.9 M | $ 6.83 | 1.08 % | $ 37.2 M | USA |
 |
AtriCure
ATRC
|
-40 M | $ 41.66 | -1.76 % | $ 1.96 B | USA |
 |
electroCore
ECOR
|
-19.3 M | $ 5.62 | 11.73 % | $ 31 K | USA |
 |
Haemonetics Corporation
HAE
|
222 M | $ 82.2 | -2.19 % | $ 4.14 B | USA |
 |
AngioDynamics
ANGO
|
-40 M | $ 9.97 | -0.8 % | $ 407 M | USA |
 |
Harvard Bioscience
HBIO
|
1.89 M | $ 0.64 | -1.79 % | $ 27.1 M | USA |
 |
The Cooper Companies
COO
|
683 M | $ 83.71 | 0.69 % | $ 16.7 B | USA |
 |
LeMaitre Vascular
LMAT
|
52.3 M | $ 84.83 | -0.25 % | $ 1.9 B | USA |
 |
Glaukos Corporation
GKOS
|
-129 M | $ 113.09 | -0.93 % | $ 5.48 B | USA |
 |
InfuSystem Holdings
INFU
|
1.65 M | $ 8.61 | -4.01 % | $ 178 M | USA |
 |
Isoray
ISR
|
-90.9 M | - | 0.03 % | $ 108 M | USA |
 |
Nephros
NEPH
|
-1.59 M | $ 4.89 | -2.5 % | $ 50.8 M | USA |
 |
Utah Medical Products
UTMD
|
16.8 M | $ 59.83 | 1.87 % | $ 217 M | USA |
 |
Intuitive Surgical
ISRG
|
2.35 B | $ 587.18 | 0.36 % | $ 209 B | USA |
 |
Microbot Medical
MBOT
|
-9.86 M | $ 2.08 | -5.02 % | $ 21.2 M |  Israel |
 |
Milestone Scientific
MLSS
|
-6.76 M | $ 0.3 | 1.23 % | $ 23.9 M | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
-1.04 B | $ 23.57 | -0.23 % | $ 4.06 B | USA |
 |
OraSure Technologies
OSUR
|
-28.2 M | $ 2.63 | -1.13 % | $ 196 M | USA |
 |
Pro-Dex
PDEX
|
10.7 M | $ 41.51 | 0.51 % | $ 136 M | USA |
 |
Repligen Corporation
RGEN
|
47.7 M | $ 166.85 | 0.26 % | $ 9.3 M | USA |
 |
ResMed
RMD
|
1 B | $ 252.15 | 0.49 % | $ 36.8 B | USA |
 |
BioLife Solutions
BLFS
|
-7.13 M | $ 24.8 | -0.6 % | $ 1.14 B | USA |
 |
STERIS plc
STE
|
867 M | $ 258.0 | -1.03 % | $ 25.4 B | USA |
 |
Stereotaxis
STXS
|
-21.8 M | $ 2.53 | -2.13 % | $ 204 M | USA |
 |
Retractable Technologies
RVP
|
-21.1 M | $ 0.76 | -2.53 % | $ 22.8 M | USA |
 |
STAAR Surgical Company
STAA
|
-12.6 M | $ 22.06 | -1.96 % | $ 1.08 B | USA |
 |
Teleflex Incorporated
TFX
|
151 M | $ 112.75 | 2.49 % | $ 5.28 B | USA |
 |
West Pharmaceutical Services
WST
|
570 M | $ 275.51 | 0.1 % | $ 20.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-879 M | $ 12.76 | 2.2 % | $ 2.59 B | USA |